Journal of Education, Health and Sport
September 24, 2026
Anna Kamosińska, Julia Pająk, Olga Sławatyniec et al.
Treatment-resistant depression (TRD) in adolescents remains a major clinical challenge because of the limited efficacy of conventional antidepressants and the high risk of suicidal behavior. Ketamine has emerged as a rapidly acting antidepressant with a unique glutamatergic mechanism, promoting neuroplasticity and reducing neuroinflammation. Clinical studies demonstrate significant symptom...
Journal of Affective Disorders
September 23, 2026
Erin Curran, Kristina T. Kumpf, Mina Ansari et al.
Ketamine/esketamine produce rapid antidepressant effects, with growing interest in how acute subjective experiences and the surrounding set and setting shape clinical outcomes. Little is known about how audiovisual adjustments during ketamine/esketamine treatment influence comfort, tolerability, or patient experience, despite their common use in clinical practice. Virtual reality (VR) is one...
Journal of Personalized Medicine
September 23, 2026
Aleksandra Metelska, Wojciech Ziemichód, Hanna Karakuła-juchnowicz
Objectives: A significant problem in the treatment of depressive disorders is the growing number of cases of so-called treatment-resistant depression (TRD). There is evidence of ketamine’s effectiveness in treating TRD, with response rates ranging from 40% to 90%. This review aimed to map available studies on peripheral biomarkers of response to ketamine and esketamine in the treatment of...
Neuropsychopharmacology
September 21, 2026
Balwinder Singh, Hossam M Ali, Alessandro Miola et al.
Disrupted excitation-inhibition (E/I) balance involving GABA and glutamate (Glu) is implicated in the pathophysiology of depression. Ketamine, an NMDA receptor antagonist with rapid antidepressant properties, may modulate this balance, yet proton magnetic resonance spectroscopy (¹H-MRS) studies report inconsistent findings regarding the direction, magnitude, and timing of neurochemical effects....
International Journal of Innovative Technologies in Social Science
September 21, 2026
Mateusz Gawin, Emilia Koziara, Mateusz Gadzina et al.
Major depressive disorder (MDD) is one of the leading causes of disability worldwide. A substantial proportion of patients fail to achieve remission through standard monoaminergic therapies, meeting the clinical criteria for treatment-resistant depression (TRD). TRD is associated with significant clinical morbidity and a profound economic burden on healthcare systems. This review evaluates the...
Expert Opinion on Therapeutic Targets
September 21, 2026
Sixtine Fleury, Katherine M. Nautiyal
INTRODUCTION: Depressive and anxiety disorders impose a substantial public health burden, yet current serotonergic therapies are limited by delayed onset, modest remission rates, and adverse side effects. Here we put forward the serotonin 1B receptor (5-HT1BR) as an important therapeutic target for mood related pathology. AREAS COVERED: We synthesize converging evidence from human and...
arXiv (Cornell University)
September 19, 2026
Muhammad Jawad Chowdhury, Sultanus Salehin, Akib Jayed Islam
preprint
Depression severity among patients with chronic or acute medical conditions is influenced by a complex interaction of baseline psychological state, demographic characteristics, clinical context, and engagement with behavioral interventions. This paper presents an interpretable machine-learning analysis of a multi-center longitudinal clinical cohort to predict Beck Depression Inventory-II...
BMC Psychology
September 19, 2026
I Jónsdottir, Anna Kristín Þorsteinsdóttir, Jóhanna Kr. Steingrímsdóttir et al.
Mindfulness-Based Cognitive Therapy (MBCT) has strong empirical support for preventing relapse in recurrent depression. This study aimed to evaluate whether adding MBCT as a follow-up intervention after an outpatient interdisciplinary rehabilitation programme benefits individuals with current moderate-to-severe depressive symptoms as well as those with minimal depressive symptoms at the start...
Journal of Neural Transmission
September 19, 2026
Guilherme Lodetti, Henrique Redivo, Amanda Gomes Teixeira et al.
Pharmacotherapy for depression is commonly prescribed, yet fewer than half of patients achieve remission with a single treatment. Many also experience intolerable side effects, highlighting the need for new treatment approaches. Classic psychedelics interact with the serotonin (5-HT) receptor class and are therefore strongly involved in the treatment of psychiatric illnesses such as depression,...
Journal of allied health
September 18, 2026
Kent E Irwin, Elizabeth Campione, Hannah Bargouthi et al.
Mental health conditions are prevalent among graduate health professions students and can negatively impact academic performance, well-being, and relationships. This systematic review evaluated the effectiveness of mind-body therapies (MBTs) on anxiety, burnout, depression, and stress in graduate health professions students. Five healthcare/academic databases were searched from 2008 through...
Psychiatry Research Neuroimaging
September 17, 2026
Juliana Lima Constantino, Jesca E. de Jager, Jasper O. Nuninga et al.
Antidepressant treatments, including conventional antidepressants and (es)ketamine, may reverse default mode network (DMN) resting-state functional connectivity (rsFC) alterations related to major depressive disorder (MDD). Despite these agents having distinct initial action mechanisms, both likely share downstream effects that lead to structural and functional adaptations in MDD-related neural...
Quality in Sport
September 17, 2026
Maciej Krzysztof Kisielewski, Natalia Fidut, Jakub Skrzypek et al.
Introduction and objective: Major depressive disorder (MDD) is a heterogeneous psychiatric condition characterized by affective, cognitive and somatic symptoms that considerably impair daily functioning. It is defined clinically by prolonged low mood, diminished interest or pleasure, and a range of associated disturbances, including changes in cognitive skills, appetite, and sleep patterns....
Journal of Huntington's Disease
September 17, 2026
Carsten Saft, Julia Jessen, David Kiefner et al.
Depression and suicidal ideation are common in Huntington's disease (HD). We report a 60-year-old male with HD who suffered from treatment-resistant depression with intermittent suicidal thoughts for 20 years, irritability and apathy. Despite multiple trials of antidepressants, no sustained improvement was achieved. Under nasal esketamine treatment his mood improved dramatically after three...
Frontiers in Psychology
September 17, 2026
Diana Brito Pearmain, Mark Kennedy, Karoly Schlosser
BackgroundPostgraduate students are six times more susceptible to mental health challenges than the general adult population, making it imperative to identify effective initiatives to support them. This is particularly relevant for master’s and doctorate students undertaking distance-learning programmes as this is a dimension of the student experience that remains unexplored. Meditation...
npj Mental Health Research
September 16, 2026
Orly Lipsitz, Ryan M Brudner, Zoe Doyle et al.
Cluster B personality disorders (PDs) are highly comorbid with depression and are associated with attenuated antidepressant response. No clinical trials to date have reported on psilocybin-assisted psychotherapy (PAP) in comorbid treatment-resistant depression (TRD) and PDs. This is the first clinical trial to describe a subgroup of ten participants with a comorbid PD ( n = 9 cluster B; n = 1...
Frontiers in Psychiatry
September 15, 2026
Serena Chiara Civardi, Filippo Besana, Federico Durbano et al.
Background Treatment-resistant depression (TRD) is a major clinical challenge, with many patients failing to respond to conventional antidepressants. Psychedelic compounds such as psilocybin and ayahuasca have recently gained attention as potential rapid-acting therapies. Beyond their neurobiological effects, methodological, ethical, and real-world applicability concerns are critical for...
Psychiatry Research
September 14, 2026
Kelei Xiao, Yealin Woo, Christine E. Dri et al.
Cognitive impairment is a core feature of major depressive disorder (MDD) and bipolar disorder (BD). Most conventional antidepressants do not have direct and clinically relevant procognitive effects. Ketamine and esketamine are effective in treating treatment-resistant depression (TRD). Herein, this systematic review aims to evaluate the effects of both pharmacotherapeutics on cognitive...
Orvosi hetilap
September 13, 2026
Szabolcs Kéri
Over the past five years, the literature on the psychiatric use of psychedelic and related treatments has expanded substantially. Several randomized controlled trials and pooled analyses have been conducted in mood disorders, treatment-resistant depression, and post-traumatic stress disorder. Trial methodology, however, remains a fundamental source of uncertainty, and despite the popularity of...
International Journal of Innovative Technologies in Social Science
September 11, 2026
Marta Borkowska, Małgorzata Witaszczyk, Alicja Sołtan et al.
Background: Ketamine and esketamine have been studied as rapid-acting interventions in adults with depressive disorders and suicidal ideation, but findings vary across populations, settings, comparators, routes, and outcome measures. Aim: To examine their effects on suicidal ideation within the first 24 hours and to identify factors contributing to variability across studies. Methods: This...
medRxiv
September 11, 2026
Srdjan Sumarac, Tristan Lawson, Leonardo Favi Bocca et al.
preprint
Ketamine and subcallosal cingulate (SCC) deep brain stimulation (DBS) have each shown antidepressant effects in treatment-resistant depression, yet how ketamine modulates SCC physiology during chronic stimulation remains poorly understood. We analyzed 5,907 hours of bilateral SCC sensing, 485 participant-triggered recordings across 193 days, 47 ketamine dosing episodes, and an in-clinic...